Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported topline results from a Phase 2 clinical trial evaluating a dissolvable microneedle patch designed to deliver chemotherapy directly into basal cell …
Medicus Pharma Reports Phase 2 Results for Skin Cancer Patch Read More
WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) said it has initiated a randomized, placebo-controlled Phase 1b proof-of-concept trial of its investigational antibody ATI-052 in patients with asthma, as it …
Aclaris Initiates Phase 1b Trial of ATI-052 in Asthma Read More
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it achieved the primary and all secondary endpoints in a Phase 3 trial of QTORIN 3.9% rapamycin gel for microcystic lymphatic …
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder Read More
PHILADELPHIA, PA — Virion Therapeutics, LLC said it presented data at the 33rd Conference on Retroviruses and Opportunistic Infections in Denver showing that a single intramuscular dose of its investigational …
Virion Reports VRON-0200 Data in Chronic Hepatitis B Study Read More
MALVERN, PA — NexEos Bio Vision Health said that the U.S. Food and Drug Administration has cleared its Investigational New Drug application to begin a Phase II/III clinical trial of …
NexEos Bio Vision Health Wins FDA Clearance for NTX-1024 Trial Read More
WASHINGTON, D.C. — The Food and Drug Administration has released draft guidance outlining a new pathway to approve highly individualized treatments for ultra-rare diseases and has granted expedited approval to …
FDA Unveils Ultra-Rare Therapy Path, Fast-Tracks Lung Drug Read More
NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) announced completion of a 90-patient Phase 2 study evaluating its investigational COVID-19 treatment ratutrelvir against PAXLOVID® and provided an update on development …
Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update Read More
DOYLESTOWN, PA — Aprea Therapeutics Inc. (Nasdaq: APRE) reported additional preliminary data from its ongoing Phase 1 ACESOT-1051 trial showing a second unconfirmed partial response in a patient with advanced …
Aprea Reports Second Partial Response in Phase 1 APR-1051 Trial Read More
WILMINGTON, DE — AstraZeneca (NYSE: AZN) said full results from the Phase III KALOS and LOGOS trials, published in The Lancet Respiratory Medicine, showed its triple-combination inhaler BREZTRI Aerosphere significantly …
AstraZeneca Reports Phase III Results for BREZTRI in Asthma Read More
HORSHAM, PA — STRATA Skin Sciences Inc. (Nasdaq: SSKN) highlighted a February 2026 systematic review and meta-analysis that found the 308 nm excimer laser to be clinically effective in treating …
STRATA Cites Study Supporting 308 Nm Laser for Psoriasis Read More